Results 31 to 40 of about 6,967,236 (252)

Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device

open access: yesDiscover Oncology, 2023
Purpose Triple-negative breast cancer continues to be one of the leading causes of death in women, making up 7% of all cancer deaths. Tumor-treating electric fields are low-energy, low-frequency oscillating electric fields that induce an anti ...
Austin R. Smothers   +6 more
doaj   +1 more source

Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin

open access: yesBreast Cancer: Basic and Clinical Research, 2009
In the current study, we sought to examine the effects of curcumin in a specific type of breast cancer called triple negative breast cancer. These cancers lack expression of the estrogen and progesterone receptors and do not over-express HER2.
Danica L. Rowe   +3 more
doaj   +2 more sources

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]

open access: yes, 2012
Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe   +16 more
core   +2 more sources

Qualitative exploration of patients’ experiences with Intrabeam TARGeted Intraoperative radioTherapy (TARGIT-IORT) and External-Beam RadioTherapy Treatment (EBRT) for breast cancer

open access: yesBMJ Open
Objective To gather a deep qualitative understanding of the perceived benefits and impacts of External-Beam RadioTherapy (EBRT) and TARGeted Intraoperative radioTherapy (TARGIT-IORT) using Intrabeam to assess how the treatments affected patient/care ...
Jayant S Vaidya   +10 more
doaj   +1 more source

Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing

open access: yes, 2017
Background: MicroRNAs (miRNAs) are short, non-coding RNA molecules that play critical roles in human malignancy. However, the regulatory characteristics of miRNAs in triple-negative breast cancer, a phenotype of breast cancer that does not express the ...
Chang, Yao-Yin;Kuo, Wen-Hung;Hung, Jui-Hui;Lee, Chien-Yueh;Lee, Yung-Hua;Chang, Ya-Chu;Lin, Wen-Chun;Shen, Cheng-Ying;Huang, Chiun-Sheng;Hsieh, Fon-Jou;Lai, Liang-Chuan;Tsai, Mong-Hsun;Chang, King-Jen;Chuang, Eric Y.   +1 more
core   +1 more source

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk [PDF]

open access: yes, 2013
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were
Side, Lucy E.,   +999 more
core   +4 more sources

GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation

open access: yes, 2018
Background Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, lacking effective targeted therapies, and whose underlying mechanisms are still unclear.
Liu, Jingjing   +7 more
core   +1 more source

Association of Parity with Triple Negative Breast Cancer, A Case Control Study

open access: yesPakistan Armed Forces Medical Journal, 2023
Objective: To find out association between number of children and triple negative breast cancer among females presenting at a tertiary care hospital of Karachi. Study Design: Case control study.
Batool Aslam Memon   +5 more
doaj   +1 more source

Management Options in Triple-Negative Breast Cancer

open access: yesBreast Cancer: Basic and Clinical Research, 2011
Notorious for its poor prognosis and aggressive nature, triple-negative breast cancer (TNBC) is a heterogeneous disease entity. The nature of its biological specificity, which is similar to basal-like cancers, tumors arising in BRCA1 mutation carriers ...
Christina A. Minami   +2 more
doaj   +2 more sources

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer [PDF]

open access: yes, 2022
Breast cancer; Drug safetyCàncer de mama; Seguretat dels medicamentsCáncer de mama; Seguridad de los medicamentosSacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload.
Tolaney, Sara M   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy